Alfuzosin hydrochloride

FDA Drug Profile — Alfuzosin hydrochloride

Alfuzosin hydrochloride is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including Alfuzosin hydrochloride. Available dosage form: tablet, extended release.

Drug details

Generic Name
Alfuzosin hydrochloride
Brand Names
Alfuzosin hydrochloride
Application Number
ANDA203192
Sponsor
Bryant Ranch Prepack
NDC Codes
5
Dosage Forms
TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
ALFUZOSIN HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Alfuzosin hydrochloride extended-release tablets, USP are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Alfuzosin hydrochloride extended-release tablet is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. (1) Important Limitations of Use: Alfuzosin hydrochloride extended-release tablets are not indicated for treatment of hypertension. ( 1.1 ) Alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population. ( 1.1 , 8.4 , 12.3 ) 1.1 Important Limitations of Use Alfuzosin hydrochloride extended-release tablets, USP are not indicated for the treatment of hypertension. Alfuzosin hydrochloride extended-release tablets, USP are not indicated for use in the pediatric population. 1.1 Important Limitations of Use Alfuzosin hydrochloride extended-release tablets, USP are not indicated for the treatment of hypertension. Alfuzosin hydrochloride extended-release tablets, USP are not indicated for use in the pediatric population.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.